|
Orthologous residues
|
|
DARPP‑32 (human): S102‑p, DARPP‑32 (mouse): S97‑p, DARPP‑32 (rat): S102‑p, DARPP‑32 (cow): S102‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'brain, nucleus accumbens', 'brain, striatum', 293 (epithelial)
|
|
Cellular systems studied:
cell lines, primary cells, tissue
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
PHOSPHATASE
|
PPP2CA (mouse)
|
phospho-antibody, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
SKF81297
|
|
|
|
decrease
|
|
|
forskolin
|
|
|
|
decrease
|
|
|
okadaic acid
|
forskolin
|
|
|
inhibit treatment-induced decrease
|
|
|
okadaic acid
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, phosphorylation
|
|
Comments:
histone H3 phosphorylation
|